Tempest Therapeutics (TPST) Fundamental Analysis: Revenue, Earnings & Valuation

2.63 / 10

Underperform

Fundamental assessment rates TPST as Underperform with a 2.6/10 score. Profit‑MV and Cash‑MV are modestly positive, inventory turnover is strong, yet Asset‑MV and Revenue‑MV are negative, gross margin is low, and income‑tax ratio is zero, indicating overall weak fundamentals.

Analysis Checks(6/10)

Revenue-MV

Value-0.28

Score1/3

Weight12.61%

1M Return5.44%

Inventory turnover ratio

Value47.57

Score3/3

Weight15.31%

1M Return6.65%

Gross profit margin (%)

Value36.91

Score1/3

Weight0.60%

1M Return0.36%

Profit-MV

Value0.41

Score2/3

Weight14.40%

1M Return6.36%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight0.35%

1M Return0.21%

Current assets turnover ratio

Value1.78

Score2/3

Weight3.31%

1M Return1.91%

Fixed assets turnover ratio

Value7899.90

Score3/3

Weight3.05%

1M Return1.76%

Cost of sales ratio (%)

Value70.30

Score3/3

Weight7.61%

1M Return4.08%

Asset-MV

Value-0.48

Score1/3

Weight28.65%

1M Return11.48%

Cash-MV

Value-0.09

Score2/3

Weight14.11%

1M Return6.19%

Is TPST fundamentally strong?

TPST scores 2.63/10 on fundamentals and holds a Premium valuation at present. Backed by its -174.63% ROE, 0.00% net margin, -0.54 P/E ratio, 3.69 P/B ratio, and 51.11% earnings growth, these metrics solidify its Underperform investment rating.